ArticleDrugs & aging2026
Clinical and Economic Outcomes of Korea's National Polypharmacy Management Program for Hospitalized Older Adults: 90-Day Readmission and Healthcare Costs.
Article in Drugs & aging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPolypharmacy is a significant health concern associated with adverse outcomes in older adults. To mitigate these risks, Korea's National Health Insurance Service implemented a hospital-based, pilot polypharmacy management program.
objectiveWe aimed to evaluate the clinical and economic effectiveness of the polypharmacy management program in beneficiaries aged ≥ 65 years.
methodsThis retrospective cohort study evaluated the polypharmacy management program implemented across 34 hospitals (2020-21). The program targeted hospitalized patients with at least one chronic condition receiving either ten or more medications or five or more medications plus an additional high-risk factor. To address the lack of randomization, an external historical control group was established by linking pilot data with the nationwide National Health Insurance Service claims database. Propensity score matching was performed on the entire cohort with subsequent analyses restricted to those aged ≥ 65 years. The primary outcome was 90-day readmission, analyzed using Cox proportional hazards regression. A cost-benefit analysis was performed from payer and societal perspectives.
resultsThe final analysis included 1135 intervention and 1125 control patients. Polypharmacy management program participants showed a lower risk of readmission compared with controls (adjusted hazard ratio = 0.85; 95% confidence interval 0.75-0.96). While emergency department visits did not differ significantly, the intervention group incurred significantly lower hospitalization costs (USD$6400 vs USD$6740, P = 0.005). The program demonstrated economic viability, yielding a benefit-cost ratio of 3.8 from a payer perspective.
conclusionsThe polypharmacy management program effectively reduced readmissions and generated substantial cost savings. These findings underscore the importance of integrating data-driven medication management into national healthcare strategies to improve patient safety and financial sustainability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.